#caspofungin

[dr-afsaeed]

Butyrolactol A enhances caspofungin efficacy via flippase inhibition in drug-resistant fungi - Research

Chen et al. identify the natural product butyrolactol A as an inhibitor of the phospholipid flippase Apt1-Cdc50, which it locks in a nonfunctional state. By disrupting membrane homeostasis and enhancing drug uptake, butyrolactol A restores echinocandin efficacy against intrinsically resistant fungal pathogens, including Cryptococcus and Candida auris. Read more about this post… Credits:…

[chemwhat]

Pneumocandin B0 CAS#: 135575-42-7

IdentificationPhysical DataSpectraRoute of Synthesis (ROS)Safety and HazardsOther Data

Identification

Product NamePneumocandin B0IUPAC NameN--6--11,20,21,25-tetrahydroxy-15--2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricycloheptacosan-18-yl]-10,12-dimethyltetradecanamide Molecular Structure

CAS Registry Number 135575-42-7EINECS NumberNo data availableMDL NumberNo data availableBeilstein Registry NumberNo data availableSynonymspneumocandin B0, pneumocandin Bo, pneumocandin B, pneumocandin B0, L-688, 786 CAS 135575-42-7 CAS: 135575-42-7 CAS No.: 135575-42-7 Molecular FormulaC50H80N8O17 Molecular Weight1065.2136 SMILES CCC(C)CC(C)CCCCCCCCC(=O)N1C((NC(=O)2(CCN2C(=O)(NC(=O)(NC(=O)3C(CN3C(=O)(NC1=O)(C)O)O)((c4ccc(cc4)O)O)O)(CC(=O)N)O)O)O)O InChIInChI=1S/C50H80N8O17/c1-5-25(2)20-26(3)12-10-8-6-7-9-11-13-37(66)52-31-22-35(64)46(71)56-48(73)41-33(62)18-19-57(41)50(75)39(34(63)23-36(51)65)54-47(72)40(43(68)42(67)28-14-16-29(60)17-15-28)55-45(70)32-21-30(61)24-58(32)49(74)38(27(4)59)53-44(31)69/h14-17,25-27,30-35,38-43,46,59-64,67-68,71H,5-13,18-24H2,1-4H3,(H2,51,65)(H,52,66)(H,53,69)(H,54,72)(H,55,70)(H,56,73)/t25?,26?,27-,30-,31+,32+,33+,34-,35-,38+,39+,40+,41+,42+,43+,46-/m1/s1 InChI KeyDQXPFAADCTZLNL-ZESADUFFSA-N Canonical SMILESCCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CC(=O)N)O)O)O)O Patent InformationPatent IDTitlePublication DateUS2014/58082 INTERMEDIATE FOR SYNTHESIZING CASPOFUNGIN AND PREPARATION METHOD THEREOF 2014

Physical Data

AppearanceOff white powder SolubilityNo data availableBoiling point1442.9±65.0 °C(Predicted) Flash PointNo data available Refractive indexNo data available SensitivityNo data available Description (Association (MCS))Solvent (Association (MCS))Temperature (Association (MCS)), °CPartner (Association (MCS))Stability constant of the complex with ...CCl424.94-FluorophenolStability constant of the complex with ... aq. HNO325AgNO3Enthalpy of associationacetonitrile25iodineNMR spectrum of the complexCDCl3Cu(2,4-dichloro-benzoate)2

Spectra

Description (NMR Spectroscopy)Nucleus (NMR Spectroscopy)Solvents (NMR Spectroscopy)Comment (NMR Spectroscopy) Chemical shifts1Htetradeuteriomethanol Chemical shifts13Ctetradeuteriomethanol Spin-spin coupling constants tetradeuteriomethanol 1H-1H. Description (UV/VIS Spectroscopy)Solvent (UV/VIS Spectroscopy)Absorption Maxima (UV/VIS), nmExt./Abs. Coefficient, l·mol-1cm-1Absorption maximamethanol 27615

Route of Synthesis (ROS)

Route-of-Synthesis-ROS-of-Pneumocandin-B0-CAS-135575-42-7 ConditionsYieldWith trifluoroacetic acid; phenylboronic acid In acetonitrile at -50 - -45℃; for 2.5h; Inert atmosphere; Experimental Procedure Under nitrogen gas protection, acetonitrile (100 ml), the compound of formula (2) (5.0 g), phenylboronic acid (0.90 g) and 3-mercaptophenol (1.80 g) were uniformly stirred and the temperature was raised to -50 to -45°C And trifluoroacetic acid (1.05 ml) was added dropwise. After the dropwise addition, the mixture was reacted at -50 to -45°C for about 2.5 hours. After confirming the completion of the reaction by TLC monitoring, the reaction was stopped and an aqueous solution of NaOAc (1.15 g NaOAc dissolved in 25 ml of water) was added slowly, and the temperature was raised to 20 ° C and stirred for 2 hours. A large amount of solid was precipitated, the temperature was lowered to 0 ° C or lower, and the filtrate was subjected to third washing with 60 ml of acetonitrile / water = 9: 1 (V / V), followed by vacuum drying for 5 hours, 3b (4.65 g, yield 93%). 93%With trifluorormethanesulfonic acid; phenylboronic acid In acetonitrile at -50 - -45℃; for 2.5h; Inert atmosphere;0.27

Safety and Hazards

Pictogram(s)

SignalDangerGHS Hazard StatementsH315 (92.31%): Causes skin irritation H317 (15.38%): May cause an allergic skin reaction H318 (92.31%): Causes serious eye damage H334 (15.38%): May cause allergy or asthma symptoms or breathing difficulties if inhaled H335 (15.38%): May cause respiratory irritation H400 (92.31%): Very toxic to aquatic life Information may vary between notifications depending on impurities, additives, and other factors. Precautionary Statement CodesP261, P264, P271, P272, P273, P280, P285, P302+P352, P304+P340, P304+P341, P305+P351+P338, P310, P312, P321, P332+P313, P333+P313, P342+P311, P362, P363, P391, P403+P233, P405, and P501 (The corresponding statement to each P-code can be found at the GHS Classification page.)

Other Data

TransportationNot dangerous goodsUnder the room temperature and away from lightHS Code294200StorageUnder the room temperature and away from lightShelf Life1 yearMarket PriceUSD DruglikenessLipinski rules componentMolecular Weight1065.23 logP3.701 HBA24 HBD15 Matching Lipinski Rules1Veber rules componentPolar Surface Area (PSA)411.28 Rotatable Bond (RotB)21Matching Veber Rules0 BioactivityIn vitro: EfficacyQuantitative Results pXParameterValue (qual)Value (quant)UnitBiological Species TargetBioassayEffect7.25MFC (minimum fungicidal concentration)(Antifungal activity) =0.06µg/mL Candida tropicalis 7.15IC50 70nM In Vitro (others) antifungal agent 7.15 IC50 =0.07µMCandida albicans Inhibitor 7.15IC50(Beta-(1,3)-D-glucan synthesis) =70nM Candida albicans MY1208 Inhibitor6.95MFC (minimum fungicidal concentration)(Minimum Inhibitory Concentration) =0.12µg/mL Candida tropicalis MY1012 6.63MFC (minimum fungicidal concentration) =0.25μg/mlCandida albicans 6.63MFC (minimum fungicidal concentration) =0.25μg/mlCandida albicans MY1208 6.63MFC (minimum fungicidal concentration)(Minimum Inhibitory Concentration) =0.5μg/ml Candida albicans MY1055 6.03MFC (minimum fungicidal concentration)=1μg/mlKluyveromyces marxianus MY2099 5.73MFC (minimum fungicidal concentration)(Minimum Inhibitory Concentration) =2µg/mL Candida parapsilosis MY1010 5.42MFC (minimum fungicidal concentration)(Antifungal activity) =4µg/mL Candida parapsilosis4.69IC50 20.23 µM In Vitro (others)3.92MIC 128 mg/L In Vitro (others) fungistatic agent ZI (zone of inhibition) 8mmIn Vitro (others) fungistatic agent MED99.9(Reduction (99.9%) of viable CFUs recoverable from mouse kidneys infected with Candida albicans (MY1208)) =6mg/kgmouse Quantitative Results1 of 9Effectfungistatic agent Biological material Aspergillus fumigatus Assay Description Bioassay : 35 deg C; potato dextrose agar 16 clinical strains (MF5668, CLY315, CLY522, CLY523 among them); in vitro; agar dilution diffusion method (Acar, J.F. 1986. Disk susceptibility test, p. 27-63. In V. Lorian (ed.) Antibiotics in laboratory medicine); 1.2E5 CFU/ml inoculum Results critical concentration, CC 0.03 - 0.05 mg/l 2 of 9 Effect Hemolytic Assay Description Target : CD-1 mouse whole blood Bioassay : unwashed erythrocyte hemolysis assay; room temperature Results MLC, minimum lytic concentration active 3.13 mg/l 3 of 9Effect Hemolytic Biological material human Assay Description Bioassay : unwashed erythrocyte hemolysis assay; room temperature Results MLC, minimum lytic concentration active 25 mg/l 4 of 9Effect antifungal agent Assay Description Target : Candida albicans MY1055 Bioassay : time-killing assay Results time-kill curve; fungicide 5 of 9Results glucan synthesis inhibition in a Candida albicans membrane assay: IC50 = 0.07 μM 6 of 9Effect fungistatic agent Assay Description Target : Aspergillus fumigatus H11-20 Bioassay : in vitro; agar diffusion assay; potato dextrose agar; 1E6 conidia/petri dish inoculum; 30 deg C; zone of inhibition measured Results critical conc. 7 of 9Effect fungistatic agent Assay DescriptionEffect : eye observable change in morphology Target : Aspergillus fumigatus H11-20 Bioassay : in vitro; broth microdilution assay; Yeast Nitrogen Base with 2 percent glucose; 1E4 condidia/well inoculum; 30 deg C Resultsmin. effective conc., MEC 0.5 mg/l 8 of 9EffectAntifungal activity against Candida albicans, Candida tropicalis, Candida parapsilosis, Candida pseudotropicalis 9 of 9Results TOKA ED99.9 = 6 mg/kg Toxicity/Safety PharmacologyQuantitative Results pXParameterValue (quant)UnitBiological Species Bioassay Effect7.58MFC90 0.25mg/L Candida albicans Cell/tumor cell: proliferation/viability/growth antifungal agent 7.28MFC90 0.5mg/L Candida tropicalis Cell/tumor cell: proliferation/viability/growth antifungal agent 6.95MFC (minimum fungicidal concentration) 0.12 - 0.5mg/L Candida albicans Cell/tumor cell: proliferation/viability/growth antifungal agent 6.68MFC90 2mg/L Candida glabrata Cell/tumor cell: proliferation/viability/growth antifungal agent 6.63MFC (minimum fungicidal concentration) 0.25 - 2mg/L Candida glabrata Cell/tumor cell: proliferation/viability/growth antifungal agent 6.33MFC (minimum fungicidal concentration) 0.5 - 64 mg/LCryptococcus neoformansCell/tumor cell: proliferation/viability/growthantifungal agent 6.03MFC50 1mg/L Kluyveromyces marxianus Cell/tumor cell: proliferation/viability/growth antifungal agent 5.73MFC50 2mg/L Pichia kudriavzevii Cell/tumor cell: proliferation/viability/growth antifungal agent 5.42MFC (minimum fungicidal concentration) 4-128mg/L Meyerozyma guilliermondii Cell/tumor cell: proliferation/viability/growth antifungal agent 5.18MFC9064mg/L Meyerozyma guilliermondii Cell/tumor cell: proliferation/viability/growth antifungal agent 5.12MFC (minimum fungicidal concentration) 8mg/L Clavispora lusitaniae Cell/tumor cell: proliferation/viability/growth antifungal agent 4.88MIC90 128mg/L Aspergillus niger Cell/tumor cell: proliferation/viability/growth antifungal agent 3.92MIC 128mg/L Aspergillus flavus Cell/tumor cell: proliferation/viability/growth antifungal agent Use PatternPneumocandin B0 CAS 135575-42-7 is starting material for production of antifungal cyclohexapeptide compounds. Pneumocandin B0 CAS 135575-42-7 is used as the pharmaceutical intermediates of the Caspofungin which is a lyophilized preparation. Read the full article

[chemwhat]

Pneumocandin B0 CAS#: 135575-42-7

IdentificationPhysical DataSpectraRoute of Synthesis (ROS)Safety and HazardsOther Data

Identification

Product NamePneumocandin B0IUPAC NameN--6--11,20,21,25-tetrahydroxy-15--2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricycloheptacosan-18-yl]-10,12-dimethyltetradecanamide Molecular Structure

CAS Registry Number 135575-42-7EINECS NumberNo data availableMDL NumberNo data availableBeilstein Registry NumberNo data availableSynonymspneumocandin B0, pneumocandin Bo, pneumocandin B, pneumocandin B0, L-688, 786 CAS 135575-42-7 CAS: 135575-42-7 CAS No.: 135575-42-7 Molecular FormulaC50H80N8O17 Molecular Weight1065.2136 SMILES CCC(C)CC(C)CCCCCCCCC(=O)N1C((NC(=O)2(CCN2C(=O)(NC(=O)(NC(=O)3C(CN3C(=O)(NC1=O)(C)O)O)((c4ccc(cc4)O)O)O)(CC(=O)N)O)O)O)O InChIInChI=1S/C50H80N8O17/c1-5-25(2)20-26(3)12-10-8-6-7-9-11-13-37(66)52-31-22-35(64)46(71)56-48(73)41-33(62)18-19-57(41)50(75)39(34(63)23-36(51)65)54-47(72)40(43(68)42(67)28-14-16-29(60)17-15-28)55-45(70)32-21-30(61)24-58(32)49(74)38(27(4)59)53-44(31)69/h14-17,25-27,30-35,38-43,46,59-64,67-68,71H,5-13,18-24H2,1-4H3,(H2,51,65)(H,52,66)(H,53,69)(H,54,72)(H,55,70)(H,56,73)/t25?,26?,27-,30-,31+,32+,33+,34-,35-,38+,39+,40+,41+,42+,43+,46-/m1/s1 InChI KeyDQXPFAADCTZLNL-ZESADUFFSA-N Canonical SMILESCCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CC(=O)N)O)O)O)O Patent InformationPatent IDTitlePublication DateUS2014/58082 INTERMEDIATE FOR SYNTHESIZING CASPOFUNGIN AND PREPARATION METHOD THEREOF 2014

Physical Data

AppearanceOff white powder SolubilityNo data availableBoiling point1442.9±65.0 °C(Predicted) Flash PointNo data available Refractive indexNo data available SensitivityNo data available Description (Association (MCS))Solvent (Association (MCS))Temperature (Association (MCS)), °CPartner (Association (MCS))Stability constant of the complex with ...CCl424.94-FluorophenolStability constant of the complex with ... aq. HNO325AgNO3Enthalpy of associationacetonitrile25iodineNMR spectrum of the complexCDCl3Cu(2,4-dichloro-benzoate)2

Spectra

Description (NMR Spectroscopy)Nucleus (NMR Spectroscopy)Solvents (NMR Spectroscopy)Comment (NMR Spectroscopy) Chemical shifts1Htetradeuteriomethanol Chemical shifts13Ctetradeuteriomethanol Spin-spin coupling constants tetradeuteriomethanol 1H-1H. Description (UV/VIS Spectroscopy)Solvent (UV/VIS Spectroscopy)Absorption Maxima (UV/VIS), nmExt./Abs. Coefficient, l·mol-1cm-1Absorption maximamethanol 27615

Route of Synthesis (ROS)

Route-of-Synthesis-ROS-of-Pneumocandin-B0-CAS-135575-42-7 ConditionsYieldWith trifluoroacetic acid; phenylboronic acid In acetonitrile at -50 - -45℃; for 2.5h; Inert atmosphere; Experimental Procedure Under nitrogen gas protection, acetonitrile (100 ml), the compound of formula (2) (5.0 g), phenylboronic acid (0.90 g) and 3-mercaptophenol (1.80 g) were uniformly stirred and the temperature was raised to -50 to -45°C And trifluoroacetic acid (1.05 ml) was added dropwise. After the dropwise addition, the mixture was reacted at -50 to -45°C for about 2.5 hours. After confirming the completion of the reaction by TLC monitoring, the reaction was stopped and an aqueous solution of NaOAc (1.15 g NaOAc dissolved in 25 ml of water) was added slowly, and the temperature was raised to 20 ° C and stirred for 2 hours. A large amount of solid was precipitated, the temperature was lowered to 0 ° C or lower, and the filtrate was subjected to third washing with 60 ml of acetonitrile / water = 9: 1 (V / V), followed by vacuum drying for 5 hours, 3b (4.65 g, yield 93%). 93%With trifluorormethanesulfonic acid; phenylboronic acid In acetonitrile at -50 - -45℃; for 2.5h; Inert atmosphere;0.27

Safety and Hazards

Pictogram(s)

SignalDangerGHS Hazard StatementsH315 (92.31%): Causes skin irritation H317 (15.38%): May cause an allergic skin reaction H318 (92.31%): Causes serious eye damage H334 (15.38%): May cause allergy or asthma symptoms or breathing difficulties if inhaled H335 (15.38%): May cause respiratory irritation H400 (92.31%): Very toxic to aquatic life Information may vary between notifications depending on impurities, additives, and other factors. Precautionary Statement CodesP261, P264, P271, P272, P273, P280, P285, P302+P352, P304+P340, P304+P341, P305+P351+P338, P310, P312, P321, P332+P313, P333+P313, P342+P311, P362, P363, P391, P403+P233, P405, and P501 (The corresponding statement to each P-code can be found at the GHS Classification page.)

Other Data

TransportationNot dangerous goodsUnder the room temperature and away from lightHS Code294200StorageUnder the room temperature and away from lightShelf Life1 yearMarket PriceUSD DruglikenessLipinski rules componentMolecular Weight1065.23 logP3.701 HBA24 HBD15 Matching Lipinski Rules1Veber rules componentPolar Surface Area (PSA)411.28 Rotatable Bond (RotB)21Matching Veber Rules0 BioactivityIn vitro: EfficacyQuantitative Results pXParameterValue (qual)Value (quant)UnitBiological Species TargetBioassayEffect7.25MFC (minimum fungicidal concentration)(Antifungal activity) =0.06µg/mL Candida tropicalis 7.15IC50 70nM In Vitro (others) antifungal agent 7.15 IC50 =0.07µMCandida albicans Inhibitor 7.15IC50(Beta-(1,3)-D-glucan synthesis) =70nM Candida albicans MY1208 Inhibitor6.95MFC (minimum fungicidal concentration)(Minimum Inhibitory Concentration) =0.12µg/mL Candida tropicalis MY1012 6.63MFC (minimum fungicidal concentration) =0.25μg/mlCandida albicans 6.63MFC (minimum fungicidal concentration) =0.25μg/mlCandida albicans MY1208 6.63MFC (minimum fungicidal concentration)(Minimum Inhibitory Concentration) =0.5μg/ml Candida albicans MY1055 6.03MFC (minimum fungicidal concentration)=1μg/mlKluyveromyces marxianus MY2099 5.73MFC (minimum fungicidal concentration)(Minimum Inhibitory Concentration) =2µg/mL Candida parapsilosis MY1010 5.42MFC (minimum fungicidal concentration)(Antifungal activity) =4µg/mL Candida parapsilosis4.69IC50 20.23 µM In Vitro (others)3.92MIC 128 mg/L In Vitro (others) fungistatic agent ZI (zone of inhibition) 8mmIn Vitro (others) fungistatic agent MED99.9(Reduction (99.9%) of viable CFUs recoverable from mouse kidneys infected with Candida albicans (MY1208)) =6mg/kgmouse Quantitative Results1 of 9Effectfungistatic agent Biological material Aspergillus fumigatus Assay Description Bioassay : 35 deg C; potato dextrose agar 16 clinical strains (MF5668, CLY315, CLY522, CLY523 among them); in vitro; agar dilution diffusion method (Acar, J.F. 1986. Disk susceptibility test, p. 27-63. In V. Lorian (ed.) Antibiotics in laboratory medicine); 1.2E5 CFU/ml inoculum Results critical concentration, CC 0.03 - 0.05 mg/l 2 of 9 Effect Hemolytic Assay Description Target : CD-1 mouse whole blood Bioassay : unwashed erythrocyte hemolysis assay; room temperature Results MLC, minimum lytic concentration active 3.13 mg/l 3 of 9Effect Hemolytic Biological material human Assay Description Bioassay : unwashed erythrocyte hemolysis assay; room temperature Results MLC, minimum lytic concentration active 25 mg/l 4 of 9Effect antifungal agent Assay Description Target : Candida albicans MY1055 Bioassay : time-killing assay Results time-kill curve; fungicide 5 of 9Results glucan synthesis inhibition in a Candida albicans membrane assay: IC50 = 0.07 μM 6 of 9Effect fungistatic agent Assay Description Target : Aspergillus fumigatus H11-20 Bioassay : in vitro; agar diffusion assay; potato dextrose agar; 1E6 conidia/petri dish inoculum; 30 deg C; zone of inhibition measured Results critical conc. 7 of 9Effect fungistatic agent Assay DescriptionEffect : eye observable change in morphology Target : Aspergillus fumigatus H11-20 Bioassay : in vitro; broth microdilution assay; Yeast Nitrogen Base with 2 percent glucose; 1E4 condidia/well inoculum; 30 deg C Resultsmin. effective conc., MEC 0.5 mg/l 8 of 9EffectAntifungal activity against Candida albicans, Candida tropicalis, Candida parapsilosis, Candida pseudotropicalis 9 of 9Results TOKA ED99.9 = 6 mg/kg Toxicity/Safety PharmacologyQuantitative Results pXParameterValue (quant)UnitBiological Species Bioassay Effect7.58MFC90 0.25mg/L Candida albicans Cell/tumor cell: proliferation/viability/growth antifungal agent 7.28MFC90 0.5mg/L Candida tropicalis Cell/tumor cell: proliferation/viability/growth antifungal agent 6.95MFC (minimum fungicidal concentration) 0.12 - 0.5mg/L Candida albicans Cell/tumor cell: proliferation/viability/growth antifungal agent 6.68MFC90 2mg/L Candida glabrata Cell/tumor cell: proliferation/viability/growth antifungal agent 6.63MFC (minimum fungicidal concentration) 0.25 - 2mg/L Candida glabrata Cell/tumor cell: proliferation/viability/growth antifungal agent 6.33MFC (minimum fungicidal concentration) 0.5 - 64 mg/LCryptococcus neoformansCell/tumor cell: proliferation/viability/growthantifungal agent 6.03MFC50 1mg/L Kluyveromyces marxianus Cell/tumor cell: proliferation/viability/growth antifungal agent 5.73MFC50 2mg/L Pichia kudriavzevii Cell/tumor cell: proliferation/viability/growth antifungal agent 5.42MFC (minimum fungicidal concentration) 4-128mg/L Meyerozyma guilliermondii Cell/tumor cell: proliferation/viability/growth antifungal agent 5.18MFC9064mg/L Meyerozyma guilliermondii Cell/tumor cell: proliferation/viability/growth antifungal agent 5.12MFC (minimum fungicidal concentration) 8mg/L Clavispora lusitaniae Cell/tumor cell: proliferation/viability/growth antifungal agent 4.88MIC90 128mg/L Aspergillus niger Cell/tumor cell: proliferation/viability/growth antifungal agent 3.92MIC 128mg/L Aspergillus flavus Cell/tumor cell: proliferation/viability/growth antifungal agent Use PatternPneumocandin B0 CAS 135575-42-7 is starting material for production of antifungal cyclohexapeptide compounds. Pneumocandin B0 CAS 135575-42-7 is used as the pharmaceutical intermediates of the Caspofungin which is a lyophilized preparation. Read the full article

[chemwhat]

Pneumocandin B0 CAS#: 135575-42-7

IdentificationPhysical DataSpectraRoute of Synthesis (ROS)Safety and HazardsOther Data

Identification

Product NamePneumocandin B0IUPAC NameN--6--11,20,21,25-tetrahydroxy-15--2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricycloheptacosan-18-yl]-10,12-dimethyltetradecanamide Molecular Structure

CAS Registry Number 135575-42-7EINECS NumberNo data availableMDL NumberNo data availableBeilstein Registry NumberNo data availableSynonymspneumocandin B0, pneumocandin Bo, pneumocandin B, pneumocandin B0, L-688, 786 CAS 135575-42-7 CAS: 135575-42-7 CAS No.: 135575-42-7 Molecular FormulaC50H80N8O17 Molecular Weight1065.2136 SMILES CCC(C)CC(C)CCCCCCCCC(=O)N1C((NC(=O)2(CCN2C(=O)(NC(=O)(NC(=O)3C(CN3C(=O)(NC1=O)(C)O)O)((c4ccc(cc4)O)O)O)(CC(=O)N)O)O)O)O InChIInChI=1S/C50H80N8O17/c1-5-25(2)20-26(3)12-10-8-6-7-9-11-13-37(66)52-31-22-35(64)46(71)56-48(73)41-33(62)18-19-57(41)50(75)39(34(63)23-36(51)65)54-47(72)40(43(68)42(67)28-14-16-29(60)17-15-28)55-45(70)32-21-30(61)24-58(32)49(74)38(27(4)59)53-44(31)69/h14-17,25-27,30-35,38-43,46,59-64,67-68,71H,5-13,18-24H2,1-4H3,(H2,51,65)(H,52,66)(H,53,69)(H,54,72)(H,55,70)(H,56,73)/t25?,26?,27-,30-,31+,32+,33+,34-,35-,38+,39+,40+,41+,42+,43+,46-/m1/s1 InChI KeyDQXPFAADCTZLNL-ZESADUFFSA-N Canonical SMILESCCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CC(=O)N)O)O)O)O Patent InformationPatent IDTitlePublication DateUS2014/58082 INTERMEDIATE FOR SYNTHESIZING CASPOFUNGIN AND PREPARATION METHOD THEREOF 2014

Physical Data

AppearanceOff white powder SolubilityNo data availableBoiling point1442.9±65.0 °C(Predicted) Flash PointNo data available Refractive indexNo data available SensitivityNo data available Description (Association (MCS))Solvent (Association (MCS))Temperature (Association (MCS)), °CPartner (Association (MCS))Stability constant of the complex with ...CCl424.94-FluorophenolStability constant of the complex with ... aq. HNO325AgNO3Enthalpy of associationacetonitrile25iodineNMR spectrum of the complexCDCl3Cu(2,4-dichloro-benzoate)2

Spectra

Description (NMR Spectroscopy)Nucleus (NMR Spectroscopy)Solvents (NMR Spectroscopy)Comment (NMR Spectroscopy) Chemical shifts1Htetradeuteriomethanol Chemical shifts13Ctetradeuteriomethanol Spin-spin coupling constants tetradeuteriomethanol 1H-1H. Description (UV/VIS Spectroscopy)Solvent (UV/VIS Spectroscopy)Absorption Maxima (UV/VIS), nmExt./Abs. Coefficient, l·mol-1cm-1Absorption maximamethanol 27615

Route of Synthesis (ROS)

Route-of-Synthesis-ROS-of-Pneumocandin-B0-CAS-135575-42-7 ConditionsYieldWith trifluoroacetic acid; phenylboronic acid In acetonitrile at -50 - -45℃; for 2.5h; Inert atmosphere; Experimental Procedure Under nitrogen gas protection, acetonitrile (100 ml), the compound of formula (2) (5.0 g), phenylboronic acid (0.90 g) and 3-mercaptophenol (1.80 g) were uniformly stirred and the temperature was raised to -50 to -45°C And trifluoroacetic acid (1.05 ml) was added dropwise. After the dropwise addition, the mixture was reacted at -50 to -45°C for about 2.5 hours. After confirming the completion of the reaction by TLC monitoring, the reaction was stopped and an aqueous solution of NaOAc (1.15 g NaOAc dissolved in 25 ml of water) was added slowly, and the temperature was raised to 20 ° C and stirred for 2 hours. A large amount of solid was precipitated, the temperature was lowered to 0 ° C or lower, and the filtrate was subjected to third washing with 60 ml of acetonitrile / water = 9: 1 (V / V), followed by vacuum drying for 5 hours, 3b (4.65 g, yield 93%). 93%With trifluorormethanesulfonic acid; phenylboronic acid In acetonitrile at -50 - -45℃; for 2.5h; Inert atmosphere;0.27

Safety and Hazards

Pictogram(s)

SignalDangerGHS Hazard StatementsH315 (92.31%): Causes skin irritation H317 (15.38%): May cause an allergic skin reaction H318 (92.31%): Causes serious eye damage H334 (15.38%): May cause allergy or asthma symptoms or breathing difficulties if inhaled H335 (15.38%): May cause respiratory irritation H400 (92.31%): Very toxic to aquatic life Information may vary between notifications depending on impurities, additives, and other factors. Precautionary Statement CodesP261, P264, P271, P272, P273, P280, P285, P302+P352, P304+P340, P304+P341, P305+P351+P338, P310, P312, P321, P332+P313, P333+P313, P342+P311, P362, P363, P391, P403+P233, P405, and P501 (The corresponding statement to each P-code can be found at the GHS Classification page.)

Other Data

TransportationNot dangerous goodsUnder the room temperature and away from lightHS Code294200StorageUnder the room temperature and away from lightShelf Life1 yearMarket PriceUSD DruglikenessLipinski rules componentMolecular Weight1065.23 logP3.701 HBA24 HBD15 Matching Lipinski Rules1Veber rules componentPolar Surface Area (PSA)411.28 Rotatable Bond (RotB)21Matching Veber Rules0 BioactivityIn vitro: EfficacyQuantitative Results pXParameterValue (qual)Value (quant)UnitBiological Species TargetBioassayEffect7.25MFC (minimum fungicidal concentration)(Antifungal activity) =0.06µg/mL Candida tropicalis 7.15IC50 70nM In Vitro (others) antifungal agent 7.15 IC50 =0.07µMCandida albicans Inhibitor 7.15IC50(Beta-(1,3)-D-glucan synthesis) =70nM Candida albicans MY1208 Inhibitor6.95MFC (minimum fungicidal concentration)(Minimum Inhibitory Concentration) =0.12µg/mL Candida tropicalis MY1012 6.63MFC (minimum fungicidal concentration) =0.25μg/mlCandida albicans 6.63MFC (minimum fungicidal concentration) =0.25μg/mlCandida albicans MY1208 6.63MFC (minimum fungicidal concentration)(Minimum Inhibitory Concentration) =0.5μg/ml Candida albicans MY1055 6.03MFC (minimum fungicidal concentration)=1μg/mlKluyveromyces marxianus MY2099 5.73MFC (minimum fungicidal concentration)(Minimum Inhibitory Concentration) =2µg/mL Candida parapsilosis MY1010 5.42MFC (minimum fungicidal concentration)(Antifungal activity) =4µg/mL Candida parapsilosis4.69IC50 20.23 µM In Vitro (others)3.92MIC 128 mg/L In Vitro (others) fungistatic agent ZI (zone of inhibition) 8mmIn Vitro (others) fungistatic agent MED99.9(Reduction (99.9%) of viable CFUs recoverable from mouse kidneys infected with Candida albicans (MY1208)) =6mg/kgmouse Quantitative Results1 of 9Effectfungistatic agent Biological material Aspergillus fumigatus Assay Description Bioassay : 35 deg C; potato dextrose agar 16 clinical strains (MF5668, CLY315, CLY522, CLY523 among them); in vitro; agar dilution diffusion method (Acar, J.F. 1986. Disk susceptibility test, p. 27-63. In V. Lorian (ed.) Antibiotics in laboratory medicine); 1.2E5 CFU/ml inoculum Results critical concentration, CC 0.03 - 0.05 mg/l 2 of 9 Effect Hemolytic Assay Description Target : CD-1 mouse whole blood Bioassay : unwashed erythrocyte hemolysis assay; room temperature Results MLC, minimum lytic concentration active 3.13 mg/l 3 of 9Effect Hemolytic Biological material human Assay Description Bioassay : unwashed erythrocyte hemolysis assay; room temperature Results MLC, minimum lytic concentration active 25 mg/l 4 of 9Effect antifungal agent Assay Description Target : Candida albicans MY1055 Bioassay : time-killing assay Results time-kill curve; fungicide 5 of 9Results glucan synthesis inhibition in a Candida albicans membrane assay: IC50 = 0.07 μM 6 of 9Effect fungistatic agent Assay Description Target : Aspergillus fumigatus H11-20 Bioassay : in vitro; agar diffusion assay; potato dextrose agar; 1E6 conidia/petri dish inoculum; 30 deg C; zone of inhibition measured Results critical conc. 7 of 9Effect fungistatic agent Assay DescriptionEffect : eye observable change in morphology Target : Aspergillus fumigatus H11-20 Bioassay : in vitro; broth microdilution assay; Yeast Nitrogen Base with 2 percent glucose; 1E4 condidia/well inoculum; 30 deg C Resultsmin. effective conc., MEC 0.5 mg/l 8 of 9EffectAntifungal activity against Candida albicans, Candida tropicalis, Candida parapsilosis, Candida pseudotropicalis 9 of 9Results TOKA ED99.9 = 6 mg/kg Toxicity/Safety PharmacologyQuantitative Results pXParameterValue (quant)UnitBiological Species Bioassay Effect7.58MFC90 0.25mg/L Candida albicans Cell/tumor cell: proliferation/viability/growth antifungal agent 7.28MFC90 0.5mg/L Candida tropicalis Cell/tumor cell: proliferation/viability/growth antifungal agent 6.95MFC (minimum fungicidal concentration) 0.12 - 0.5mg/L Candida albicans Cell/tumor cell: proliferation/viability/growth antifungal agent 6.68MFC90 2mg/L Candida glabrata Cell/tumor cell: proliferation/viability/growth antifungal agent 6.63MFC (minimum fungicidal concentration) 0.25 - 2mg/L Candida glabrata Cell/tumor cell: proliferation/viability/growth antifungal agent 6.33MFC (minimum fungicidal concentration) 0.5 - 64 mg/LCryptococcus neoformansCell/tumor cell: proliferation/viability/growthantifungal agent 6.03MFC50 1mg/L Kluyveromyces marxianus Cell/tumor cell: proliferation/viability/growth antifungal agent 5.73MFC50 2mg/L Pichia kudriavzevii Cell/tumor cell: proliferation/viability/growth antifungal agent 5.42MFC (minimum fungicidal concentration) 4-128mg/L Meyerozyma guilliermondii Cell/tumor cell: proliferation/viability/growth antifungal agent 5.18MFC9064mg/L Meyerozyma guilliermondii Cell/tumor cell: proliferation/viability/growth antifungal agent 5.12MFC (minimum fungicidal concentration) 8mg/L Clavispora lusitaniae Cell/tumor cell: proliferation/viability/growth antifungal agent 4.88MIC90 128mg/L Aspergillus niger Cell/tumor cell: proliferation/viability/growth antifungal agent 3.92MIC 128mg/L Aspergillus flavus Cell/tumor cell: proliferation/viability/growth antifungal agent Use PatternPneumocandin B0 CAS 135575-42-7 is starting material for production of antifungal cyclohexapeptide compounds Read the full article

[chemwhat]

Pneumocandin B0 CAS#: 135575-42-7

IdentificationPhysical DataSpectraRoute of Synthesis (ROS)Safety and HazardsOther Data

Identification

Product NamePneumocandin B0IUPAC NameN--6--11,20,21,25-tetrahydroxy-15--2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricycloheptacosan-18-yl]-10,12-dimethyltetradecanamide Molecular Structure

CAS Registry Number 135575-42-7EINECS NumberNo data availableMDL NumberNo data availableBeilstein Registry NumberNo data availableSynonymspneumocandin B0, pneumocandin Bo, pneumocandin B, pneumocandin B0, L-688, 786 CAS 135575-42-7 CAS: 135575-42-7 CAS No.: 135575-42-7 Molecular FormulaC50H80N8O17 Molecular Weight1065.2136 SMILES CCC(C)CC(C)CCCCCCCCC(=O)N1C((NC(=O)2(CCN2C(=O)(NC(=O)(NC(=O)3C(CN3C(=O)(NC1=O)(C)O)O)((c4ccc(cc4)O)O)O)(CC(=O)N)O)O)O)O InChIInChI=1S/C50H80N8O17/c1-5-25(2)20-26(3)12-10-8-6-7-9-11-13-37(66)52-31-22-35(64)46(71)56-48(73)41-33(62)18-19-57(41)50(75)39(34(63)23-36(51)65)54-47(72)40(43(68)42(67)28-14-16-29(60)17-15-28)55-45(70)32-21-30(61)24-58(32)49(74)38(27(4)59)53-44(31)69/h14-17,25-27,30-35,38-43,46,59-64,67-68,71H,5-13,18-24H2,1-4H3,(H2,51,65)(H,52,66)(H,53,69)(H,54,72)(H,55,70)(H,56,73)/t25?,26?,27-,30-,31+,32+,33+,34-,35-,38+,39+,40+,41+,42+,43+,46-/m1/s1 InChI KeyDQXPFAADCTZLNL-ZESADUFFSA-N Canonical SMILESCCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CC(=O)N)O)O)O)O Patent InformationPatent IDTitlePublication DateUS2014/58082 INTERMEDIATE FOR SYNTHESIZING CASPOFUNGIN AND PREPARATION METHOD THEREOF 2014

Physical Data

AppearanceOff white powder SolubilityNo data availableBoiling point1442.9±65.0 °C(Predicted) Flash PointNo data available Refractive indexNo data available SensitivityNo data available Description (Association (MCS))Solvent (Association (MCS))Temperature (Association (MCS)), °CPartner (Association (MCS))Stability constant of the complex with ...CCl424.94-FluorophenolStability constant of the complex with ... aq. HNO325AgNO3Enthalpy of associationacetonitrile25iodineNMR spectrum of the complexCDCl3Cu(2,4-dichloro-benzoate)2

Spectra

Description (NMR Spectroscopy)Nucleus (NMR Spectroscopy)Solvents (NMR Spectroscopy)Comment (NMR Spectroscopy) Chemical shifts1Htetradeuteriomethanol Chemical shifts13Ctetradeuteriomethanol Spin-spin coupling constants tetradeuteriomethanol 1H-1H. Description (UV/VIS Spectroscopy)Solvent (UV/VIS Spectroscopy)Absorption Maxima (UV/VIS), nmExt./Abs. Coefficient, l·mol-1cm-1Absorption maximamethanol 27615

Route of Synthesis (ROS)

Route-of-Synthesis-ROS-of-Pneumocandin-B0-CAS-135575-42-7 ConditionsYieldWith trifluoroacetic acid; phenylboronic acid In acetonitrile at -50 - -45℃; for 2.5h; Inert atmosphere; Experimental Procedure Under nitrogen gas protection, acetonitrile (100 ml), the compound of formula (2) (5.0 g), phenylboronic acid (0.90 g) and 3-mercaptophenol (1.80 g) were uniformly stirred and the temperature was raised to -50 to -45°C And trifluoroacetic acid (1.05 ml) was added dropwise. After the dropwise addition, the mixture was reacted at -50 to -45°C for about 2.5 hours. After confirming the completion of the reaction by TLC monitoring, the reaction was stopped and an aqueous solution of NaOAc (1.15 g NaOAc dissolved in 25 ml of water) was added slowly, and the temperature was raised to 20 ° C and stirred for 2 hours. A large amount of solid was precipitated, the temperature was lowered to 0 ° C or lower, and the filtrate was subjected to third washing with 60 ml of acetonitrile / water = 9: 1 (V / V), followed by vacuum drying for 5 hours, 3b (4.65 g, yield 93%). 93%With trifluorormethanesulfonic acid; phenylboronic acid In acetonitrile at -50 - -45℃; for 2.5h; Inert atmosphere;0.27

Safety and Hazards

Pictogram(s)

SignalDangerGHS Hazard StatementsH315 (92.31%): Causes skin irritation H317 (15.38%): May cause an allergic skin reaction H318 (92.31%): Causes serious eye damage H334 (15.38%): May cause allergy or asthma symptoms or breathing difficulties if inhaled H335 (15.38%): May cause respiratory irritation H400 (92.31%): Very toxic to aquatic life Information may vary between notifications depending on impurities, additives, and other factors. Precautionary Statement CodesP261, P264, P271, P272, P273, P280, P285, P302+P352, P304+P340, P304+P341, P305+P351+P338, P310, P312, P321, P332+P313, P333+P313, P342+P311, P362, P363, P391, P403+P233, P405, and P501 (The corresponding statement to each P-code can be found at the GHS Classification page.)

Other Data

TransportationNot dangerous goodsUnder the room temperature and away from lightHS Code294200StorageUnder the room temperature and away from lightShelf Life1 yearMarket PriceUSD DruglikenessLipinski rules componentMolecular Weight1065.23 logP3.701 HBA24 HBD15 Matching Lipinski Rules1Veber rules componentPolar Surface Area (PSA)411.28 Rotatable Bond (RotB)21Matching Veber Rules0 BioactivityIn vitro: EfficacyQuantitative Results pXParameterValue (qual)Value (quant)UnitBiological Species TargetBioassayEffect7.25MFC (minimum fungicidal concentration)(Antifungal activity) =0.06µg/mL Candida tropicalis 7.15IC50 70nM In Vitro (others) antifungal agent 7.15 IC50 =0.07µMCandida albicans Inhibitor 7.15IC50(Beta-(1,3)-D-glucan synthesis) =70nM Candida albicans MY1208 Inhibitor6.95MFC (minimum fungicidal concentration)(Minimum Inhibitory Concentration) =0.12µg/mL Candida tropicalis MY1012 6.63MFC (minimum fungicidal concentration) =0.25μg/mlCandida albicans 6.63MFC (minimum fungicidal concentration) =0.25μg/mlCandida albicans MY1208 6.63MFC (minimum fungicidal concentration)(Minimum Inhibitory Concentration) =0.5μg/ml Candida albicans MY1055 6.03MFC (minimum fungicidal concentration)=1μg/mlKluyveromyces marxianus MY2099 5.73MFC (minimum fungicidal concentration)(Minimum Inhibitory Concentration) =2µg/mL Candida parapsilosis MY1010 5.42MFC (minimum fungicidal concentration)(Antifungal activity) =4µg/mL Candida parapsilosis4.69IC50 20.23 µM In Vitro (others)3.92MIC 128 mg/L In Vitro (others) fungistatic agent ZI (zone of inhibition) 8mmIn Vitro (others) fungistatic agent MED99.9(Reduction (99.9%) of viable CFUs recoverable from mouse kidneys infected with Candida albicans (MY1208)) =6mg/kgmouse Quantitative Results1 of 9Effectfungistatic agent Biological material Aspergillus fumigatus Assay Description Bioassay : 35 deg C; potato dextrose agar 16 clinical strains (MF5668, CLY315, CLY522, CLY523 among them); in vitro; agar dilution diffusion method (Acar, J.F. 1986. Disk susceptibility test, p. 27-63. In V. Lorian (ed.) Antibiotics in laboratory medicine); 1.2E5 CFU/ml inoculum Results critical concentration, CC 0.03 - 0.05 mg/l 2 of 9 Effect Hemolytic Assay Description Target : CD-1 mouse whole blood Bioassay : unwashed erythrocyte hemolysis assay; room temperature Results MLC, minimum lytic concentration active 3.13 mg/l 3 of 9Effect Hemolytic Biological material human Assay Description Bioassay : unwashed erythrocyte hemolysis assay; room temperature Results MLC, minimum lytic concentration active 25 mg/l 4 of 9Effect antifungal agent Assay Description Target : Candida albicans MY1055 Bioassay : time-killing assay Results time-kill curve; fungicide 5 of 9Results glucan synthesis inhibition in a Candida albicans membrane assay: IC50 = 0.07 μM 6 of 9Effect fungistatic agent Assay Description Target : Aspergillus fumigatus H11-20 Bioassay : in vitro; agar diffusion assay; potato dextrose agar; 1E6 conidia/petri dish inoculum; 30 deg C; zone of inhibition measured Results critical conc. 7 of 9Effect fungistatic agent Assay DescriptionEffect : eye observable change in morphology Target : Aspergillus fumigatus H11-20 Bioassay : in vitro; broth microdilution assay; Yeast Nitrogen Base with 2 percent glucose; 1E4 condidia/well inoculum; 30 deg C Resultsmin. effective conc., MEC 0.5 mg/l 8 of 9EffectAntifungal activity against Candida albicans, Candida tropicalis, Candida parapsilosis, Candida pseudotropicalis 9 of 9Results TOKA ED99.9 = 6 mg/kg Toxicity/Safety PharmacologyQuantitative Results pXParameterValue (quant)UnitBiological Species Bioassay Effect7.58MFC90 0.25mg/L Candida albicans Cell/tumor cell: proliferation/viability/growth antifungal agent 7.28MFC90 0.5mg/L Candida tropicalis Cell/tumor cell: proliferation/viability/growth antifungal agent 6.95MFC (minimum fungicidal concentration) 0.12 - 0.5mg/L Candida albicans Cell/tumor cell: proliferation/viability/growth antifungal agent 6.68MFC90 2mg/L Candida glabrata Cell/tumor cell: proliferation/viability/growth antifungal agent 6.63MFC (minimum fungicidal concentration) 0.25 - 2mg/L Candida glabrata Cell/tumor cell: proliferation/viability/growth antifungal agent 6.33MFC (minimum fungicidal concentration) 0.5 - 64 mg/LCryptococcus neoformansCell/tumor cell: proliferation/viability/growthantifungal agent 6.03MFC50 1mg/L Kluyveromyces marxianus Cell/tumor cell: proliferation/viability/growth antifungal agent 5.73MFC50 2mg/L Pichia kudriavzevii Cell/tumor cell: proliferation/viability/growth antifungal agent 5.42MFC (minimum fungicidal concentration) 4-128mg/L Meyerozyma guilliermondii Cell/tumor cell: proliferation/viability/growth antifungal agent 5.18MFC9064mg/L Meyerozyma guilliermondii Cell/tumor cell: proliferation/viability/growth antifungal agent 5.12MFC (minimum fungicidal concentration) 8mg/L Clavispora lusitaniae Cell/tumor cell: proliferation/viability/growth antifungal agent 4.88MIC90 128mg/L Aspergillus niger Cell/tumor cell: proliferation/viability/growth antifungal agent 3.92MIC 128mg/L Aspergillus flavus Cell/tumor cell: proliferation/viability/growth antifungal agent Use PatternPneumocandin B0 CAS 135575-42-7 is starting material for production of antifungal cyclohexapeptide compounds Read the full article

[ashwini1666-blog]

“Caspofungin Market” 2020-2025 report is a professional study on the current state of the market that focuses on the major drivers, challenges, opportunities for the leading players.

[ijtsrd]

Development and application of Liquid Chromatographic method for determination of Caspofungin Acetate in sterile, lyophilized powder for Injection

By Dr. L. Satyanarayana | Dr. Sumalatha Reddi"Development and application of Liquid Chromatographic method for determination of Caspofungin Acetate in sterile, lyophilized powder for Injection" 

Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-2 | Issue-3 , April 2018, 

URL: http://www.ijtsrd.com/papers/ijtsrd10927.pdf  

http://www.ijtsrd.com/pharmacy/pharmaceutics/10927/development-and-application-of-liquid-chromatographic-method-for-determination-of-caspofungin-acetate-in-sterile-lyophilized-powder-for-injection/dr-l-satyanarayana

paper publication, call for paper management, ugc approved journals in commerce

Caspofungin is an antifungal agent of the novel echinocandin class. Caspofungin, the first inhibitor of fungal b-1,3 glucan synthesis to receive approval by the United States Food and Drug Administration, is effective for the treatment of mucosal and invasive candidiasis and invasive aspergillosis. It is also active in vitro and in animal models against a number of other filamentous and dimorphic endemic fungi and in animal models of Pneumocystis carinii infection. Caspofungin is a water-soluble amphipathic lipopeptide is a semisynthetic derivative of pneumocandin B0, a fermentation product of Glarea lozoyensis. Developing a accurate and precise alytical method for the estimation of cagpsofungin in a sterile, lyophilized product for intravenous (IV) infusion a is very challenging, due to the formation of drug-drug and drug-excipient interactions. The present study demonstrates the applicability of chromatographic method to develop a new, sensitive, single HPLC method for the quantitative determination of antifungal agents in freeze dried powder for injection pharmaceutical dosage form. Chromatographic separation active pharmaceutical ingredient was achieved by using a isocratic elution at a flow rate of 1.0 mL/min on X-Terra RP-18 column (250mm×4.6 mm, 5-µm particle size, 100Ã… pore size) at ambient temperature. The contents of the mobile phase were 3.48 gms of Di Potassium hydrogen ortho-phosphate (0.03M) in 1000 ml of water and by adjusting the pH to 3.2 with dilute ortho-phosphoric acid (mobile phase solvent-A) and acetonitrile (mobile phase solvent-B) in a isocratic mode in the ratio of 30: 70 (v/v) of separation was used to resolute the Caspofungin. UV detection at 278 nm was employed to monitor the analytes. A linear response was observed for caspofungin over the concentration range 0.5'“6 -µg/ mL. Limit of detection (LOD) and Limit of quantification (LOQ) for Capsofungin were found to be 0.001-µg/mL, and 0.003-µg/mL respectively. 

[preventivehealthcare101-blog]

Caspofungin| Find why Caspofungin is prescribed including its typical usage, side effects and safety, interactions, warnings and ask a doctor for expert advise on Caspofungin at MediKlik.com

Mediklik Web Health Pvt Ltd is a doctor consultation online service, which is not only providing health advice for people but also help them get quality treatment with their cutting-edge tools such as Free PHR, Healthline, diagnostic tool and complete information on diseases, drugs and first-Aids.